An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, to be...

Full description

Bibliographic Details
Main Authors: Sanjay S. Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre, Claudia Galindo Tsoukas
Format: Article
Language:English
Published: Taylor & Francis Group 2023-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
dengue fever
immunogenicity
live attenuated
safety
shelf-life
tetravalent
dengue vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2023.2254964

Internet

http://dx.doi.org/10.1080/21645515.2023.2254964

Similar Items